GlobeNewswire All Public CompaniesQwen · 实盘不做把握 0/10不做原因:不是事件
北京时间·🕒 发布 04:05:00·⟳ 抓取 04:06:02·⚡ 决策 08-28 04:07:42 +1m40s·61.2 天前
Pulmonx宣布管理层将参加两场投资者会议（Wells Fargo Healthcare及Lake Street BIG10），属例行IR日程通知
该公告是标准的投资者会议参与通知，仅披露管理层将出席两场会议的日程安排，不含任何新的财务数据、产品进展、监管审批、订单、指引或任何可能改变市场预期的增量信息。历史上此类公告对股价无任何影响，属于纯噪音信号。
📄 原文GlobeNewswire All Public Companies↗ 原文
Pulmonx to Participate in Upcoming Investor Conferences
REDWOOD CITY, Calif., Aug. 27, 2026 (GLOBE NEWSWIRE) -- Pulmonx Corporation (Nasdaq: LUNG) (“Pulmonx”) a global leader…
不做 Pulmonx Corporation（LUNG.US）
公告为纯投资者会议日程通知，不含任何新增基本面信息（无财务数据、无产品进展、无监管审批、无订单、无指引变化），不构成任何方向的交易催化，属纯噪音事件
展开详情(成交明细 / 研究档案 / 原文全文 / 决策记录链)
研究档案
结论摘要
Pulmonx通过GlobeNewswire发布管理层参加两场投资者会议的日程通知（9月9日Wells Fargo Healthcare、9月10日Lake Street BIG10），均为1x1会议。公告全文不含任何新财务数据、产品更新、监管进展、客户/订单信息或指引变化，属于上市公司例行IR日程披露。此类公告在市场中完全无价格影响，不构成任何方向的交易催化。结论：不做。
🔎 新鲜度:最早出现 2026-08-27 · 扩散 low · price-in 风险 low ↗
先例如何影响了这次决策
对本次决策的影响:投资者会议参与通知属于纯噪音事件，历史上不存在可参考的价格反应先例，无需进行事件研究
方向:无适用先例
涨幅量级:无适用先例
形态:无
工具执行结果 · 成功 2 · 降级 0 · 失败 0 · 取消 0
- search_processed_events 成功 stock_tools HTTP · 2,375 ms
{"result": "search_processed_events:agent query=`lung wells fargo healthcare conference | pulmonx investor conference participation | pulmonx lake street big10`；结构化索引覆盖完整 72 小时；旧记录兼容扫描近 69.0/72 小时、11804 条本臂决策(完整)，返回 0 条候选。未命中只表示这些 agent query 表达式没有召回候选，不能据此证明消息首发或不是重复；按当前事件继续正常研判。"} - fetch_decision_experience 成功 stock_tools HTTP · 998 ms
{
原文全文
展开原文 · 1,675 字
REDWOOD CITY, Calif., Aug. 27, 2026 (GLOBE NEWSWIRE) -- Pulmonx Corporation (Nasdaq: LUNG) (“Pulmonx”) a global leader in minimally invasive treatments for severe lung disease, today announced that management will participate in the following upcoming investor conferences:
Wells Fargo Healthcare Conference
Format:
1x1 meetings
Date:
Wednesday, September 9
Location:
Boston, MA
Lake Street Best Ideas Growth (BIG10) Conference
Format: 1x1 meetings
Date: Thursday, September 10
Location: New York, NY
About Pulmonx Corporation
Pulmonx Corporation (Nasdaq: LUNG) is a global leader in minimally invasive treatments for chronic obstructive pulmonary disease (COPD). Pulmonx’s Zephyr
®
Endobronchial Valve, Chartis
®
Pulmonary Assessment System, LungTraX
®
Platform, and StratX
®
Lung Analysis Reports are designed to assess and treat patients with severe emphysema/COPD who despite medical management are still profoundly symptomatic. Pulmonx received U.S. Food and Drug Administration (FDA) Premarket Approval (PMA) to commercialize the Zephyr
®
Endobronchial Valve following its designation as a “breakthrough device.” The Zephyr Valve is commercially available in more than 25 countries, is included in global treatment guidelines and is widely considered a standard of care treatment option for improving breathing, activity and quality of life in patients with severe emphysema. For more information on the Zephyr Valves and the company, please visit
www.Pulmonx.com
.
Pulmonx
®
, AeriSeal
®
, Chartis
®
, LungTraX
®
, StratX
®
, and Zephyr
®
are registered trademarks of Pulmonx Corporation.
Contact
Brian Johnston or Webb Campbell
Gilmartin Group
investors@pulmonx.com
Wells Fargo Healthcare Conference
Format:
1x1 meetings
Date:
Wednesday, September 9
Location:
Boston, MA
Lake Street Best Ideas Growth (BIG10) Conference
Format: 1x1 meetings
Date: Thursday, September 10
Location: New York, NY
About Pulmonx Corporation
Pulmonx Corporation (Nasdaq: LUNG) is a global leader in minimally invasive treatments for chronic obstructive pulmonary disease (COPD). Pulmonx’s Zephyr
®
Endobronchial Valve, Chartis
®
Pulmonary Assessment System, LungTraX
®
Platform, and StratX
®
Lung Analysis Reports are designed to assess and treat patients with severe emphysema/COPD who despite medical management are still profoundly symptomatic. Pulmonx received U.S. Food and Drug Administration (FDA) Premarket Approval (PMA) to commercialize the Zephyr
®
Endobronchial Valve following its designation as a “breakthrough device.” The Zephyr Valve is commercially available in more than 25 countries, is included in global treatment guidelines and is widely considered a standard of care treatment option for improving breathing, activity and quality of life in patients with severe emphysema. For more information on the Zephyr Valves and the company, please visit
www.Pulmonx.com
.
Pulmonx
®
, AeriSeal
®
, Chartis
®
, LungTraX
®
, StratX
®
, and Zephyr
®
are registered trademarks of Pulmonx Corporation.
Contact
Brian Johnston or Webb Campbell
Gilmartin Group
investors@pulmonx.com
决策记录链 · 只追加
每次领取产生一条记录,重新决策追加一条并以 supersedes 指向被替代的记录(ADR 0014)。
这条决策早于决策账本(2026-10-08 起逐条追加),没有追加记录。